All In Biotech

Free tool

FAERS Monitor: Potassium Phosphates

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 212832 or its brand name (Potassium Phosphates, Potassium Phosphate, Dibasic, Potassium Phosphate, Monobasic). Reports on generic versions are filed under their own applications.

Reports

886

Serious

765

86% of reports

Hospitalization

525

Death reported

174

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea64
  • nausea62
  • pyrexia61
  • pneumonia59
  • cytokine release syndrome52
  • off label use52
  • vomiting49
  • hypotension47
  • dyspnoea44
  • acute kidney injury42
  • fatigue42
  • febrile neutropenia42
  • sepsis40
  • toxic epidermal necrolysis33
  • anaemia31

Reports by year received

View as table
YearReports
200418
200511
200623
200721
200812
200931
201028
201137
201237
201327
201436
201546
201645
201731
201832
201947
202076
202179
202275
202362
202434
202540
202638

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,273 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
cytokine release syndromeSignal5261.747.43,040
toxic epidermal necrolysisSignal3351.737.01,588
febrile neutropeniaSignal4215.011.2538
sepsisSignal408.56.3259
acute kidney injurySignal426.54.9192
hypotensionSignal475.64.2173
pneumoniaSignal594.33.4150
pyrexiaSignal614.23.3147
anaemiaSignal313.92.763
vomitingSignal492.51.943
diarrhoeaSignal642.41.950
nausea621.91.525
dyspnoea441.81.417
off label use521.41.16
fatigue421.31.02

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.